hydrochlorothiazide (HCTZ) or olmesartan
PreclinicalSmall molecule
hydrochlorothiazide (HCTZ) or olmesartan is one of 8 small molecule programs targeting Hypertensive. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Hypertensive
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Normodyne
AAlvogen Korea
Approved
Procardia
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Beta Blocker
WWeill Medical College of Cornell University
Preclinical
Standard Medical Therapy
PPost Graduate Institute of Medical Education and Research, Chandigarh
Preclinical
Calcium Channel Blocker
MMinia University
Preclinical
Antihypertensive Medication
UUniversity of Alberta
Preclinical
hydrochlorothiazide (HCTZ) or olmesartan
TThe Louis & Rachel Rudin Foundation
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details